Anti-Müllerian hormone (AMH) is the most clinically useful single-marker proxy for ovarian reserve, reflecting the total pool of small antral follicles currently recruited in the ovaries. A low AMH does not mean pregnancy is impossible through ICI, but it does signal that the reproductive window is narrowing and that aggressive treatment timelines may be warranted. Interpreting AMH in the context of a complete fertility evaluation — including antral follicle count, FSH, age, and clinical history — is essential before drawing conclusions about ICI appropriateness.
AMH Reference Ranges and What “Low” Means
AMH is measured in ng/mL or pmol/L depending on the laboratory assay. In women of reproductive age (18–35), median AMH values range from 1.5–3.5 ng/mL, with values above 1.0 ng/mL generally considered in the normal-low to normal range. Values of 0.5–1.0 ng/mL are classified as low, 0.3–0.5 ng/mL as very low, and below 0.3 ng/mL as critically low (consistent with premature ovarian insufficiency or imminent menopause). The POSEIDON classification system for poor ovarian responders categorizes women into four groups based on AMH, AFC, and age, providing standardized clinical terminology that facilitates protocol selection. For ICI purposes, AMH below 0.5 ng/mL combined with advanced age (over 36) warrants urgent reproductive evaluation and consideration of expedited treatment.
AMH is notable for its relative stability across the menstrual cycle — unlike FSH and estradiol, which fluctuate significantly between cycle phases, AMH can be measured on any cycle day. However, AMH values can be transiently suppressed by hormonal contraceptive use (oral contraceptives lower AMH by 20–40% in some studies), and values typically recover to pre-treatment levels within 2–3 months of discontinuation. Women recently off hormonal contraception should ideally wait at least two months before using AMH to assess ovarian reserve for ICI planning purposes.
How Low AMH Affects ICI Clinical Outcomes
A 2017 prospective cohort study in Fertility and Sterility by Broer et al. evaluated 750 IUI cycles and found that AMH below 0.5 ng/mL was associated with a 60% reduction in clinical pregnancy rate per cycle compared to women with AMH above 1.5 ng/mL (4.8% vs. 12.1%). Although this data is from IUI cycles, the principle applies to ICI: low ovarian reserve means fewer recruitment-capable follicles, lower probability of timely dominant follicle development, and higher rates of cycle cancellation. In ovulation induction cycles, women with low AMH often produce a suboptimal follicular response to oral agents, requiring higher gonadotropin doses and intensive monitoring.
Low AMH also correlates with higher rates of biochemical pregnancy (positive hCG that does not progress to clinical pregnancy), thought to reflect reduced oocyte quality associated with diminished reserve. In women with AMH below 0.5 ng/mL, biochemical pregnancy rates after ICI may be 25–35%, meaning that a positive pregnancy test is followed by spontaneous loss before ultrasound confirmation in a substantial proportion of cycles. This pattern can be emotionally devastating for patients who are unaware of its prevalence in low-reserve populations, making pre-cycle counseling about biochemical pregnancy rates an important part of informed consent.
Protocol Modifications for Low AMH ICI Patients
Women with low AMH who choose to pursue ICI should be offered stimulated cycles from the outset rather than natural timing attempts, because the marginal difference between natural cycle success probability and stimulated cycle success probability is more pronounced in low-reserve patients. Low-dose gonadotropin stimulation (starting at 75 IU FSH) with serial ultrasound monitoring gives the clinician the opportunity to identify the dominant follicle, confirm adequate growth, and trigger precisely — reducing the timing variability that plagues natural cycles in low-reserve women who may have shorter or irregular follicular phases. Adding luteal phase progesterone support (vaginal micronized progesterone 200 mg twice daily) from 3 days post-insemination is also standard practice given the increased luteal insufficiency risk in low AMH patients.
Dehydroepiandrosterone (DHEA) supplementation at 25–75 mg daily for 3–6 months before ICI has been proposed as a strategy to improve ovarian response in low AMH women. Several small randomized trials and a meta-analysis published in Human Reproduction in 2018 found that DHEA supplementation in women with poor ovarian reserve increased AMH levels, AFC, and clinical pregnancy rates in IVF — though ICI-specific data are more limited. DHEA is converted to androgens in granulosa cells, which enhance FSH receptor expression and improve follicular sensitivity to stimulation. Its use should be discussed with a reproductive specialist and monitored, as androgenic side effects (acne, hirsutism) occur in a minority of patients.
When to Transition from ICI to IVF with Low AMH
For women with AMH below 0.5 ng/mL, the cumulative live birth rate after six ICI cycles is substantially lower than for normo-reserve patients, and the time cost of six cycles (typically 6–12 months) represents a meaningful portion of their remaining reproductive window. Most reproductive endocrinologists recommend a maximum of two to three ICI cycles before transitioning to IVF in women with AMH below 0.5 ng/mL, particularly if age is also a factor. IVF with PGT-A allows selection of euploid embryos from a cohort of retrieved eggs, maximizing the per-transfer success probability and efficiently using the limited egg supply. For women with AMH below 0.1 ng/mL, proceeding directly to IVF without attempting ICI cycles is a reasonable recommendation given the very low probability of ICI success at this reserve level.
For a complete at-home insemination solution, the MakeAmom Babymaker Kit includes everything you need for a properly timed, sterile ICI cycle. For a complete at-home insemination solution, the His Fertility Boost includes everything you need for a properly timed, sterile ICI cycle.
Further reading across our network: IntracervicalInsemination.org · MakeAmom.com · IntracervicalInseminationKit.info
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions about your fertility care.
